Cargando…

Epi-Drugs in Heart Failure

Unveiling the secrets of genome’s flexibility does not only foster new research in the field, but also gives rise to the exploration and development of novel epigenetic-based therapies as an approach to alleviate disease phenotypes. A better understanding of chromatin biology (DNA/histone complexes)...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorica, Era, Mohammed, Shafeeq A., Ambrosini, Samuele, Calderone, Vincenzo, Costantino, Sarah, Paneni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326055/
https://www.ncbi.nlm.nih.gov/pubmed/35911511
http://dx.doi.org/10.3389/fcvm.2022.923014
_version_ 1784757191191822336
author Gorica, Era
Mohammed, Shafeeq A.
Ambrosini, Samuele
Calderone, Vincenzo
Costantino, Sarah
Paneni, Francesco
author_facet Gorica, Era
Mohammed, Shafeeq A.
Ambrosini, Samuele
Calderone, Vincenzo
Costantino, Sarah
Paneni, Francesco
author_sort Gorica, Era
collection PubMed
description Unveiling the secrets of genome’s flexibility does not only foster new research in the field, but also gives rise to the exploration and development of novel epigenetic-based therapies as an approach to alleviate disease phenotypes. A better understanding of chromatin biology (DNA/histone complexes) and non-coding RNAs (ncRNAs) has enabled the development of epigenetic drugs able to modulate transcriptional programs implicated in cardiovascular diseases. This particularly applies to heart failure, where epigenetic networks have shown to underpin several pathological features, such as left ventricular hypertrophy, fibrosis, cardiomyocyte apoptosis and microvascular dysfunction. Targeting epigenetic signals might represent a promising approach, especially in patients with heart failure with preserved ejection fraction (HFpEF), where prognosis remains poor and breakthrough therapies have yet to be approved. In this setting, epigenetics can be employed for the development of customized therapeutic approaches thus paving the way for personalized medicine. Even though the beneficial effects of epi-drugs are gaining attention, the number of epigenetic compounds used in the clinical practice remains low suggesting that more selective epi-drugs are needed. From DNA-methylation changes to non-coding RNAs, we can establish brand-new regulations for drug targets with the aim of restoring healthy epigenomes and transcriptional programs in the failing heart. In the present review, we bring the timeline of epi-drug discovery and development, thus highlighting the emerging role of epigenetic therapies in heart failure.
format Online
Article
Text
id pubmed-9326055
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93260552022-07-28 Epi-Drugs in Heart Failure Gorica, Era Mohammed, Shafeeq A. Ambrosini, Samuele Calderone, Vincenzo Costantino, Sarah Paneni, Francesco Front Cardiovasc Med Cardiovascular Medicine Unveiling the secrets of genome’s flexibility does not only foster new research in the field, but also gives rise to the exploration and development of novel epigenetic-based therapies as an approach to alleviate disease phenotypes. A better understanding of chromatin biology (DNA/histone complexes) and non-coding RNAs (ncRNAs) has enabled the development of epigenetic drugs able to modulate transcriptional programs implicated in cardiovascular diseases. This particularly applies to heart failure, where epigenetic networks have shown to underpin several pathological features, such as left ventricular hypertrophy, fibrosis, cardiomyocyte apoptosis and microvascular dysfunction. Targeting epigenetic signals might represent a promising approach, especially in patients with heart failure with preserved ejection fraction (HFpEF), where prognosis remains poor and breakthrough therapies have yet to be approved. In this setting, epigenetics can be employed for the development of customized therapeutic approaches thus paving the way for personalized medicine. Even though the beneficial effects of epi-drugs are gaining attention, the number of epigenetic compounds used in the clinical practice remains low suggesting that more selective epi-drugs are needed. From DNA-methylation changes to non-coding RNAs, we can establish brand-new regulations for drug targets with the aim of restoring healthy epigenomes and transcriptional programs in the failing heart. In the present review, we bring the timeline of epi-drug discovery and development, thus highlighting the emerging role of epigenetic therapies in heart failure. Frontiers Media S.A. 2022-07-13 /pmc/articles/PMC9326055/ /pubmed/35911511 http://dx.doi.org/10.3389/fcvm.2022.923014 Text en Copyright © 2022 Gorica, Mohammed, Ambrosini, Calderone, Costantino and Paneni. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Gorica, Era
Mohammed, Shafeeq A.
Ambrosini, Samuele
Calderone, Vincenzo
Costantino, Sarah
Paneni, Francesco
Epi-Drugs in Heart Failure
title Epi-Drugs in Heart Failure
title_full Epi-Drugs in Heart Failure
title_fullStr Epi-Drugs in Heart Failure
title_full_unstemmed Epi-Drugs in Heart Failure
title_short Epi-Drugs in Heart Failure
title_sort epi-drugs in heart failure
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326055/
https://www.ncbi.nlm.nih.gov/pubmed/35911511
http://dx.doi.org/10.3389/fcvm.2022.923014
work_keys_str_mv AT goricaera epidrugsinheartfailure
AT mohammedshafeeqa epidrugsinheartfailure
AT ambrosinisamuele epidrugsinheartfailure
AT calderonevincenzo epidrugsinheartfailure
AT costantinosarah epidrugsinheartfailure
AT panenifrancesco epidrugsinheartfailure